Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said.
Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s by targeting a known cause, rather than just treating symptoms.
